ICER Colloquium Series, Pricing in a Pandemic | Session One: Cost-Recovery Pricing


ICER Colloquium Series, Pricing in a Pandemic: Options, Debate, a Path Forward

Session One: Cost-Recovery Pricing

  • Webinar Date: July 24, 2020, from 12-1:30 pm ET
  • Speakers:
    • Afton Cissell, JD, Senior Counsel to Congressman Lloyd Doggett (D-Tex)
    • Ronny Gal, Analyst, Sanford C. Bernstein
    • David Mitchell, Founder, Patients For Affordable Drugs
    • Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Brigham and Women’s Hospital/Harvard Medical School
    • Randy Burkholder, Vice President, Policy and Research at PhRMA
  • Audience: Free and open to the public

Before the talk, take a look at our white paper on “Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19.”


The Institute for Clinical and Economic Review invites all patient organizations and the general public to attend a webinar to learn more about ICER’s mission, patient engagement, and proposed enhancements for evaluating medicines and other health care interventions. Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner. One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world.

ICER published a white paper to inform public and policy maker discussion of “Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19.”  To complement the white paper, ICER will host a three-part online colloquium series of 90-minute webinars featuring leading health policy and industry experts from around the country who will debate the advantages and disadvantages of many different potential approaches to developing and pricing medicines during a pandemic.

The first colloquium will cover cost-recovery pricing in which prices are set at a level needed to cover all the costs borne by the manufacturer in making the treatment.